187 related articles for article (PubMed ID: 33835210)
1. Diagnostic performance of the noninvasive prenatal FetoGnost RhD assay for the prediction of the fetal RhD blood group status.
Legler TJ; Lührig S; Korschineck I; Schwartz D
Arch Gynecol Obstet; 2021 Nov; 304(5):1191-1196. PubMed ID: 33835210
[TBL] [Abstract][Full Text] [Related]
2. High-throughput non-invasive prenatal testing for fetal rhesus D status in RhD-negative women not known to be sensitised to the RhD antigen: a systematic review and economic evaluation.
Saramago P; Yang H; Llewellyn A; Walker R; Harden M; Palmer S; Griffin S; Simmonds M
Health Technol Assess; 2018 Mar; 22(13):1-172. PubMed ID: 29580376
[TBL] [Abstract][Full Text] [Related]
3. High-throughput, non-invasive prenatal testing for fetal rhesus D status in RhD-negative women: a systematic review and meta-analysis.
Yang H; Llewellyn A; Walker R; Harden M; Saramago P; Griffin S; Simmonds M
BMC Med; 2019 Feb; 17(1):37. PubMed ID: 30760268
[TBL] [Abstract][Full Text] [Related]
4. Targeted antenatal anti-D prophylaxis for RhD-negative pregnant women: a systematic review.
Runkel B; Bein G; Sieben W; Sow D; Polus S; Fleer D
BMC Pregnancy Childbirth; 2020 Feb; 20(1):83. PubMed ID: 32033599
[TBL] [Abstract][Full Text] [Related]
5. High-throughput, non-invasive prenatal testing for fetal Rhesus D genotype to guide antenatal prophylaxis with anti-D immunoglobulin: a cost-effectiveness analysis.
Saramago P; Yang H; Llewellyn A; Palmer S; Simmonds M; Griffin S
BJOG; 2018 Oct; 125(11):1414-1422. PubMed ID: 29415334
[TBL] [Abstract][Full Text] [Related]
6. Targeted antenatal anti-D prophylaxis program for RhD-negative pregnant women - outcome of the first two years of a national program in Finland.
Haimila K; Sulin K; Kuosmanen M; Sareneva I; Korhonen A; Natunen S; Tuimala J; Sainio S
Acta Obstet Gynecol Scand; 2017 Oct; 96(10):1228-1233. PubMed ID: 28718198
[TBL] [Abstract][Full Text] [Related]
7. Determination of fetal RHD type in plasma of RhD negative pregnant women.
Sørensen K; Kjeldsen-Kragh J; Husby H; Akkök ÇA
Scand J Clin Lab Invest; 2018 Sep; 78(5):411-416. PubMed ID: 29869532
[TBL] [Abstract][Full Text] [Related]
8. Screening of RHD fetal genotype in RhD negative women.
Kratochvílová T; Böhmová J; Durdová V; Vodička R; Holusková I; Langová K; Lubušký M
Ceska Gynekol; 2020; 85(3):156-163. PubMed ID: 33562966
[TBL] [Abstract][Full Text] [Related]
9. Non-Invasive Prenatal Fetal Blood Group Genotype and Its Application in the Management of Hemolytic Disease of Fetus and Newborn: Systematic Review and Meta-Analysis.
Alshehri AA; Jackson DE
Transfus Med Rev; 2021 Apr; 35(2):85-94. PubMed ID: 33781630
[TBL] [Abstract][Full Text] [Related]
10. Prenatal non-invasive foetal RHD genotyping: diagnostic accuracy of a test as a guide for appropriate administration of antenatal anti-D immunoprophylaxis.
Manfroi S; Calisesi C; Fagiani P; Gabriele A; Lodi G; Nucci S; Pelliconi S; Righini L; Randi V
Blood Transfus; 2018 Nov; 16(6):514-524. PubMed ID: 29757138
[TBL] [Abstract][Full Text] [Related]
11. Implementation of high-throughput non-invasive prenatal testing for fetal RHD genotype testing in England: Results of a cross-sectional survey of maternity units and expert interviews.
Ryczek E; White J; Carolan-Rees G
Transfus Med; 2020 Aug; 30(4):287-294. PubMed ID: 32447792
[TBL] [Abstract][Full Text] [Related]
12. Antenatal
Clausen FB
Immunohematology; 2024 Apr; 40(1):15-27. PubMed ID: 38739027
[TBL] [Abstract][Full Text] [Related]
13. Noninvasive Antenatal Screening for Fetal RHD in RhD Negative Women to Guide Targeted Anti-D Prophylaxis.
Clausen FB; Rieneck K; Krog GR; Bundgaard BS; Dziegiel MH
Methods Mol Biol; 2019; 1885():347-359. PubMed ID: 30506209
[TBL] [Abstract][Full Text] [Related]
14. Report of the first nationally implemented clinical routine screening for fetal RHD in D- pregnant women to ascertain the requirement for antenatal RhD prophylaxis.
Clausen FB; Christiansen M; Steffensen R; Jørgensen S; Nielsen C; Jakobsen MA; Madsen RD; Jensen K; Krog GR; Rieneck K; Sprogøe U; Homburg KM; Grunnet N; Dziegiel MH
Transfusion; 2012 Apr; 52(4):752-8. PubMed ID: 21995641
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity of fetal RHD screening for safe guidance of targeted anti-D immunoglobulin prophylaxis: prospective cohort study of a nationwide programme in the Netherlands.
de Haas M; Thurik FF; van der Ploeg CP; Veldhuisen B; Hirschberg H; Soussan AA; Woortmeijer H; Abbink F; Page-Christiaens GC; Scheffer PG; Ellen van der Schoot C
BMJ; 2016 Nov; 355():i5789. PubMed ID: 27821701
[TBL] [Abstract][Full Text] [Related]
16. Validation of a non-invasive prenatal test for fetal RhD, C, c, E, K and Fy
Alford B; Landry BP; Hou S; Bower X; Bueno AM; Chen D; Husic B; Cantonwine DE; McElrath TF; Carozza JA; Wynn J; Hoskovec J; Gray KJ
Sci Rep; 2023 Aug; 13(1):12786. PubMed ID: 37550335
[TBL] [Abstract][Full Text] [Related]
17. The determination of the fetal D status from maternal plasma for decision making on Rh prophylaxis is feasible.
Müller SP; Bartels I; Stein W; Emons G; Gutensohn K; Köhler M; Legler TJ
Transfusion; 2008 Nov; 48(11):2292-301. PubMed ID: 18694461
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic accuracy of routine antenatal determination of fetal RHD status across gestation: population based cohort study.
Chitty LS; Finning K; Wade A; Soothill P; Martin B; Oxenford K; Daniels G; Massey E
BMJ; 2014 Sep; 349():g5243. PubMed ID: 25190055
[TBL] [Abstract][Full Text] [Related]
19. Noninvasive fetal RhD genotyping from maternal blood.
Kolialexi A; Tounta G; Mavrou A
Expert Rev Mol Diagn; 2010 Apr; 10(3):285-96. PubMed ID: 20370586
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
